Observation Study Of Carbocisteine Combined With Tiotropium Bromide In Treatment Of Stable COPD Of Group B

Objective:To investigate the clinical effect of carbocisteine combined with Tiotropium Bromide in treatment of stable COPD of group B.Methods:From September 2017 to December 2018,a total number of 60 In&Out patients with stable COPD of group B from respiratory department of the First Affiliated Hospital of Kunming Medical University,were recruited and randomly divided into the treatment(n=30)and the control(n=30)groups.The control group was prescribed with inhalation of tiotropium bromide,while the treatment group was prescribed with inhalation of tiotropium bromide combined with Carbocisteine.After 12 months of treatment,the acute exacerbation times,dyspnea index(mMRC),and pulmonary function of the two groups were observed and compared.Results:There was no significant difference in the scores of mMRC between the two groups(P>0.05)before treatment,and the scores of mMRC in two groups were both decreased after 12 months of treatment,and the reduction of the scores of mMRC in the treatment were much,lower than it in the control group(P<0.05).No significant difference was found in the FEV1 and FEV1%pred between the two groups(P>0.05)before treatment,and the FEV1 and FEV1%pred of pulmonary function in two groups were both increased after 12 months of treatment,and the improvement of FEV1 and FEV1%pred in treatment group were much higher than those in the control group(P<0.05).There was no significant difference in the acute exacerbation between two groups(P>0.05)before treatment.While the acute exacerbation in two groups were obviously decreased after 12 months of treatment,and the reduction of the acute exacerbation in treatment group were much lower than those in the control group,which is statistically significant(P<0.05).Conclusions:Carbocisteine combined with Tiotropium Bromide in treatment of stable chronic obstructive pulmonary disease of group B has a remarkable synergistic effect.It can improve the clinical symptoms and pulmonary function,reduce the frequency of acute exacerbation of patients.Hence it is worthy of recommendation in clinical management.